Neurofilament light chain associates with IVH and ROP in extremely preterm infants.

Journal

Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714

Informations de publication

Date de publication:
24 Sep 2024
Historique:
received: 12 04 2024
accepted: 03 09 2024
revised: 28 08 2024
medline: 25 9 2024
pubmed: 25 9 2024
entrez: 24 9 2024
Statut: aheadofprint

Résumé

Neurofilament light chain (NfL) is known for indicating adult brain injury, but the role of NfL in extremely preterm infants is less studied. This study examines the relationship between NfL and neurovascular morbidities in these infants. A secondary analysis of the Mega Donna Mega trial was conducted on preterm infants <28 weeks gestational age (GA). The study measured NfL levels and proteomic profiles related to the blood-brain barrier in serum from birth to term-equivalent age, investigating the association of NfL with GA, retinopathy of prematurity (ROP), intraventricular hemorrhage (IVH), and blood-brain barrier proteins. Higher NfL levels were seen in the first month in infants with severe IVH and for those born <25 weeks GA (independent of ROP or IVH). Additionally, infants born at 25-27 weeks GA with high NfL were at increased risk of developing severe ROP (independent of IVH). NfL was significantly associated with the proteins CDH5, ITGB1, and JAM-A during the first month. NfL surges after birth in extremely preterm infants, particularly in those with severe IVH and ROP, and in the most immature infants regardless of IVH or ROP severity. These findings suggest NfL as a potential predictor of neonatal morbidities, warranting further validation studies. This study shows that higher NfL levels are related to neurovascular morbidities in extremely preterm infants. The degree of immaturity seems important as infants born <25 weeks gestational age exhibited high postnatal serum NfL levels irrespective of neurovascular morbidities. Our findings suggest a potential link between NfL and neurovascular morbidities possibly affected by a more permeable blood-brain barrier.

Sections du résumé

BACKGROUND BACKGROUND
Neurofilament light chain (NfL) is known for indicating adult brain injury, but the role of NfL in extremely preterm infants is less studied. This study examines the relationship between NfL and neurovascular morbidities in these infants.
METHODS METHODS
A secondary analysis of the Mega Donna Mega trial was conducted on preterm infants <28 weeks gestational age (GA). The study measured NfL levels and proteomic profiles related to the blood-brain barrier in serum from birth to term-equivalent age, investigating the association of NfL with GA, retinopathy of prematurity (ROP), intraventricular hemorrhage (IVH), and blood-brain barrier proteins.
RESULTS RESULTS
Higher NfL levels were seen in the first month in infants with severe IVH and for those born <25 weeks GA (independent of ROP or IVH). Additionally, infants born at 25-27 weeks GA with high NfL were at increased risk of developing severe ROP (independent of IVH). NfL was significantly associated with the proteins CDH5, ITGB1, and JAM-A during the first month.
CONCLUSION CONCLUSIONS
NfL surges after birth in extremely preterm infants, particularly in those with severe IVH and ROP, and in the most immature infants regardless of IVH or ROP severity. These findings suggest NfL as a potential predictor of neonatal morbidities, warranting further validation studies.
IMPACT STATEMENT UNASSIGNED
This study shows that higher NfL levels are related to neurovascular morbidities in extremely preterm infants. The degree of immaturity seems important as infants born <25 weeks gestational age exhibited high postnatal serum NfL levels irrespective of neurovascular morbidities. Our findings suggest a potential link between NfL and neurovascular morbidities possibly affected by a more permeable blood-brain barrier.

Identifiants

DOI: 10.1038/s41390-024-03587-5 PMID: 39317698
pubmed: 39317698
doi: 10.1038/s41390-024-03587-5
pii: 10.1038/s41390-024-03587-5
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Gaetani, L. et al. Neurofilament light chain as a biomarker in neurological disorders. J. Neurol. Neurosurg. Psychiatry 90, 870–881 (2019).
pubmed: 30967444 doi: 10.1136/jnnp-2018-320106
Yuan, A. & Nixon, R. A. Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies. Front. Neurosci. 15, 689938 (2021).
pubmed: 34646114 pmcid: 8503617 doi: 10.3389/fnins.2021.689938
Sjöbom, U. et al. Analysis of brain injury biomarker neurofilament light and neurodevelopmental outcomes and retinopathy of prematurity among preterm infants. JAMA Netw. Open 4, e214138–e214138 (2021).
pubmed: 33797551 pmcid: 8019094 doi: 10.1001/jamanetworkopen.2021.4138
Depoorter, A. et al. Neurofilament light chain: blood biomarker of neonatal neuronal injury. Front Neurol. 9, 984 (2018).
pubmed: 30524361 pmcid: 6256184 doi: 10.3389/fneur.2018.00984
Kürner, K. et al. Vaginal delivery is associated with neurochemical evidence of increased neuroaxonal remodelling in infants from the Kuno-kids Health Study: cross-sectional analysis. Neonatology 119, 769–776 (2022).
pubmed: 36108619 doi: 10.1159/000526472
Agency, E. M. Letter of support of neurofilament light in childhood neurological diseases. EMADOC-1700519818-959805 (2022). https://www.ema.europa.eu/en/documents/other/letter-support-neurofilament-light-childhood-neurological-diseases_en.pdf .
Schjørring, M. E., Parkner, T., Knudsen, C. S., Tybirk, L. & Hviid, C. V. B. Neurofilament light chain: serum reference intervals in danish children aged 0-17 years. Scand. J. Clin. Lab. Investig. 83, 403–407 (2023).
doi: 10.1080/00365513.2023.2251003
Abdelhak, A. et al. Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study. Lancet Neurol. 22, 826–833 (2023).
pubmed: 37524100 doi: 10.1016/S1474-4422(23)00210-7
Stukas, S. et al. Pediatric reference intervals for serum neurofilament light and glial fibrillary acidic protein using the Canadian Laboratory Initiative on Pediatric Reference Intervals (Caliper) cohort. Clin. Chem. Lab. Med. 62, 698–705 (2024).
pubmed: 37882772 doi: 10.1515/cclm-2023-0660
Whitelaw, A., Rosengren, L. & Blennow, M. Brain specific proteins in posthaemorrhagic ventricular dilatation. Arch. Dis. Child. Fetal Neonatal Ed. 84, F90–F91 (2001).
pubmed: 11207222 pmcid: 1721221 doi: 10.1136/fn.84.2.F90
Goeral, K. et al. Early life serum neurofilament dynamics predict neurodevelopmental outcome of preterm infants. J. Neurol. 268, 2570–2577 (2021).
pubmed: 33566157 pmcid: 8217001 doi: 10.1007/s00415-021-10429-5
Molloy, C. S., Anderson, P. J., Anderson, V. A. & Doyle, L. W. The long-term outcome of extremely preterm (<28 weeks’ gestational age) infants with and without severe retinopathy of prematurity. J. Neuropsychol. 10, 276–294 (2016).
pubmed: 25809467 doi: 10.1111/jnp.12069
Huang, C. C. et al. Retinopathy of prematurity is a biomarker for pathological processes in the immature brain. Neonatology 119, 727–734 (2022).
pubmed: 36252528 doi: 10.1159/000526652
Parodi, A., Govaert, P., Horsch, S., Bravo, M. C. & Ramenghi, L. A. Cranial ultrasound findings in preterm germinal matrix haemorrhage, sequelae and outcome. Pediatr. Res 87, 13–24 (2020).
pubmed: 32218535 pmcid: 7098890 doi: 10.1038/s41390-020-0780-2
Papile, L. A., Burstein, J., Burstein, R. & Koffler, H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J. Pediatr. 92, 529–534 (1978).
pubmed: 305471 doi: 10.1016/S0022-3476(78)80282-0
Holmström, G. E. et al. Swedish national register for retinopathy of prematurity (Swedrop) and the evaluation of screening in Sweden. Arch. Ophthalmol. 130, 1418–1424 (2012).
The International Classification of Retinopathy of Prematurity Revisited. Arch. Ophthalmol. 123, 991–999 (2005).
Uher, T. et al. Neurofilament levels are associated with blood–brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. Mult. Scler. J. 27, 220–231 (2021).
doi: 10.1177/1352458520912379
Friis, T. et al. Cerebral biomarkers and blood-brain barrier integrity in preeclampsia. Cells 11, 789 (2022).
Alagaratnam, J. et al. Correlation between Csf and blood neurofilament light chain protein: a systematic review and meta-analysis. BMJ Neurol. Open 3, e000143 (2021).
pubmed: 34223154 pmcid: 8211066 doi: 10.1136/bmjno-2021-000143
Abu-Rumeileh, S. et al. The multifaceted role of neurofilament light chain protein in non-primary neurological diseases. Brain 146, 421–437 (2022).
Evers, K. S. et al. Neurofilament as neuronal injury blood marker in preeclampsia. Hypertension 71, 1178–1184 (2018).
pubmed: 29686016 doi: 10.1161/HYPERTENSIONAHA.117.10314
Gillespie, T. C. et al. Decreased levels of erythrocyte membrane arachidonic and docosahexaenoic acids are associated with retinopathy of prematurity. Investig. Ophthalmol. Vis. Sci. 63, 23 (2022).
doi: 10.1167/iovs.63.12.23
Hellström, A. et al. Association of docosahexaenoic acid and arachidonic acid serum levels with retinopathy of prematurity in preterm infants. JAMA Netw. Open 4, e2128771 (2021).
pubmed: 34648010 pmcid: 8517742 doi: 10.1001/jamanetworkopen.2021.28771
Martinat, M., Rossitto, M., Di Miceli, M. & Layé, S. Perinatal dietary polyunsaturated fatty acids in brain development, role in neurodevelopmental disorders. Nutrients 13, 1185 (2021).
pubmed: 33918517 pmcid: 8065891 doi: 10.3390/nu13041185
Hellström, A. et al. Effect of enteral lipid supplement on severe retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr. 175, 359–367 (2021).
pubmed: 33523106 doi: 10.1001/jamapediatrics.2020.5653
Gould, J. F. et al. Neonatal docosahexaenoic acid in preterm infants and intelligence at 5 years. N. Engl. J. Med. 387, 1579–1588 (2022).
pubmed: 36300974 doi: 10.1056/NEJMoa2206868
Heileson, J. L. et al. The effect of Omega-3 fatty acids on a biomarker of head trauma in NCAA football athletes: a multi-site, non-randomized study. J. Int. Soc. Sports Nutr. 18, 65 (2021).
pubmed: 34579748 pmcid: 8477477 doi: 10.1186/s12970-021-00461-1
Oliver, J. M. et al. Effect of docosahexaenoic acid on a biomarker of head trauma in American football. Med. Sci. Sports Exerc. 48, 974–982 (2016).
Thau-Zuchman, O. et al. A single injection of docosahexaenoic acid induces a pro-resolving lipid mediator profile in the injured tissue and a long-lasting reduction in neurological deficit after traumatic brain injury in mice. J. Neurotrauma 37, 66–79 (2020).
pubmed: 31256709 doi: 10.1089/neu.2019.6420
World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Jama 310, 2191–2194 (2013).
doi: 10.1001/jama.2013.281053
Nilsson, A. K. et al. Long-chain polyunsaturated fatty acids decline rapidly in milk from mothers delivering extremely preterm indicating the need for supplementation. Acta Paediatr. 107, 1020–1027 (2018).
pubmed: 29444356 pmcid: 5969106 doi: 10.1111/apa.14275
Zhong, W. et al. Dramatic changes in blood protein levels during the first week of life in extremely preterm infants. Pediatr. Res. 89, 604–612 (2021).
pubmed: 32330929 doi: 10.1038/s41390-020-0912-8
Assarsson, E. et al. Homogenous 96-plex pea immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PloS One 9, e95192 (2014).
pubmed: 24755770 pmcid: 3995906 doi: 10.1371/journal.pone.0095192
Consortium, T. U. Uniprot: the universal protein knowledgebase in 2023. Nucleic Acids Res. 51, D523–D531 (2022).
doi: 10.1093/nar/gkac1052
Volpe J. J. et al. Volpe’s Neurology of the Newborn, 6th edn. (Elsevier, 2017).
Fenton, T. R. & Kim, J. H. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatr. 13, 59 (2013).
pubmed: 23601190 pmcid: 3637477 doi: 10.1186/1471-2431-13-59
Andersson, E. A., Mallard, C. & Ek, C. J. Circulating tight-junction proteins are potential biomarkers for blood-brain barrier function in a model of neonatal hypoxic/ischemic brain injury. Fluids Barriers CNS 18, 7 (2021).
pubmed: 33568200 pmcid: 7877092 doi: 10.1186/s12987-021-00240-9
Dejana, E., Tournier-Lasserve, E. & Weinstein, B. M. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev. Cell 16, 209–221 (2009).
pubmed: 19217423 doi: 10.1016/j.devcel.2009.01.004
Martìn-Padura, I. et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J. Cell Biol. 142, 117–127 (1998).
pubmed: 9660867 pmcid: 2133024 doi: 10.1083/jcb.142.1.117
Smith, R. O. et al. Vascular permeability in retinopathy is regulated by Vegfr2 Y949 signaling to Ve-Cadherin. eLife 9, e54056 (2020).
pubmed: 32312382 pmcid: 7188482 doi: 10.7554/eLife.54056
Giannotta, M., Trani, M. & Dejana, E. Ve-Cadherin and endothelial adherens junctions: active guardians of vascular integrity. Devk Cell 26, 441–454 (2013).
doi: 10.1016/j.devcel.2013.08.020
Yamamoto, H. et al. Integrin Β1 controls Ve-Cadherin localization and blood vessel stability. Nat. Commun. 6, 6429 (2015).
pubmed: 25752958 doi: 10.1038/ncomms7429
Garzone, D. et al. Neurofilament light chain and retinal layers’ determinants and association: a population-based study. Ann. Clin. Transl. Neurol. 9, 564–569 (2022).
pubmed: 35243826 pmcid: 8994982 doi: 10.1002/acn3.51522
Seitz, C. B. et al. Serum neurofilament levels reflect outer retinal layer changes in multiple sclerosis. Ther. Adv. Neurol. Disord. 14, 17562864211003478 (2021).
pubmed: 34104217 pmcid: 8155762 doi: 10.1177/17562864211003478
Wong, Y. Y. M. et al. Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes. Neurology 93, e968–e974 (2019).
pubmed: 31383792 doi: 10.1212/WNL.0000000000008057
Boesen, M. S. et al. Increased cerebrospinal fluid chitinase 3-like 1 and neurofilament light chain in pediatric acquired demyelinating syndromes. Mult. Scler. Relat. Disord. 24, 175–183 (2018).
pubmed: 30055504 doi: 10.1016/j.msard.2018.05.017
Gram, M. et al. Hemoglobin induces inflammation after preterm intraventricular hemorrhage by methemoglobin formation. J. Neuroinflam. 10, 100 (2013).
doi: 10.1186/1742-2094-10-100
Ley, D. et al. High presence of extracellular hemoglobin in the periventricular white matter following preterm intraventricular hemorrhage. Front Physiol. 7, 330 (2016).
pubmed: 27536248 pmcid: 4971438 doi: 10.3389/fphys.2016.00330
Rees, P. et al. Preterm brain injury and neurodevelopmental outcomes: a meta-analysis. Pediatrics 150, e2022057442 (2022).
Horsch, S. et al. Randomized control trial of postnatal Rhigf-1/Rhigfbp-3 replacement in preterm infants: post-hoc analysis of its effect on brain injury. Front. Pediatr. 8, 517207 (2020).
pubmed: 33163463 pmcid: 7581737 doi: 10.3389/fped.2020.517207
Kerdiles, O., Layé, S. & Calon, F. Omega-3 polyunsaturated fatty acids and brain health: preclinical evidence for the prevention of neurodegenerative diseases. Trends Food Sci. Technol. 69, 203–213 (2017).
doi: 10.1016/j.tifs.2017.09.003
Tofiq, A. et al. Effects of peroral omega-3 fatty acid supplementation on cerebrospinal fluid biomarkers in patients with Alzheimer’s disease: a randomized controlled trial-the omegad study. J. Alzheimers Dis. 83, 1291–1301 (2021).
pubmed: 34420949 doi: 10.3233/JAD-210007
Kim, S. J. et al. Retinopathy of prematurity: a review of risk factors and their clinical significance. Surv. Ophthalmol. 63, 618–637 (2018).
pubmed: 29679617 pmcid: 6089661 doi: 10.1016/j.survophthal.2018.04.002
O’Shea, T. M. et al. Intraventricular hemorrhage and developmental outcomes at 24 months of age in extremely preterm infants. J. Child Neurol. 27, 22–29 (2012).
pubmed: 22232137 pmcid: 3724508 doi: 10.1177/0883073811424462
Bolisetty, S. et al. Intraventricular hemorrhage and neurodevelopmental outcomes in extreme preterm infants. Pediatrics 133, 55–62 (2014).
pubmed: 24379238 doi: 10.1542/peds.2013-0372
Périsset, A. et al. Impact of low-grade intraventricular hemorrhage on neurodevelopmental outcome in very preterm infants at two years of age. Early Hum. Dev. 177-178, 105721 (2023).
pubmed: 36841201 doi: 10.1016/j.earlhumdev.2023.105721
Jacobs Sariyar, A., van Pesch, V., Nassogne, M.-C., Moniotte, S. & Momeni, M. Usefulness of serum neurofilament light in the assessment of neurologic outcome in the pediatric population: a systematic literature review. Eur. J. Pediatr. 182, 1941–1948 (2023).
Lundgren, P. et al. Visual outcome at 2.5 years of age in Ω-3 and Ω-6 long-chain polyunsaturated fatty acid supplemented preterm infants: a follow-up of a randomized controlled trial. Lancet Reg. Health Eur. 32, 100696 (2023).
Ingvaldsen, S. H., Morken, T. S., Austeng, D. & Dammann, O. Visuopathy of prematurity: is retinopathy just the tip of the iceberg? Pediatr. Res. 91, 1043–1048 (2022).
pubmed: 34168272 doi: 10.1038/s41390-021-01625-0

Auteurs

Ulrika Sjöbom (U)

Learning and Leadership for Health Care Professionals, Institute of Health and Care Science at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. ulrika.sjobom@gu.se.
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. ulrika.sjobom@gu.se.
ORCID: 0000-0003-4844-2396

Annika Öhrfelt (A)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

Aldina Pivodic (A)

Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Anders K Nilsson (AK)

Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Kaj Blennow (K)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, PR China.

Henrik Zetterberg (H)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Department of Neurodegenerative Disease, University College of London Institute of Neurology, London, UK.
UK Dementia Research Institute, University College of London, London, UK.
Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.

William Hellström (W)

Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Hanna Danielsson (H)

Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Sach's Children's and Youth Hospital, Södersjukhuset, Stockholm, Sweden.

Lotta Gränse (L)

Department of Clinical Sciences, Ophthalmology, Lund University, Skåne University Hospital, Lund, Sweden.

Karin Sävman (K)

Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Region Västra Götaland, Department of Neonatology, The Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden.

Dirk Wackernagel (D)

Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden.
Division of Neonatology, Department of Pediatrics, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.

Ingrid Hansen-Pupp (I)

Department of Clinical Sciences Lund, Pediatrics, Lund University, Skåne University Hospital, Lund, Sweden.

David Ley (D)

Department of Clinical Sciences Lund, Pediatrics, Lund University, Skåne University Hospital, Lund, Sweden.

Ann Hellström (A)

Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Chatarina Löfqvist (C)

Learning and Leadership for Health Care Professionals, Institute of Health and Care Science at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Classifications MeSH